Two case studies demonstrate the difficulty, delay in recognizing this rare autoinflammatory disease
SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…
Although progress has been made in recent years, rheumatologists still have a lot of questions regarding best management practices for antiphospholipid syndrome (APS). During a session of EULAR 2022, Ricard Cervera, MD, PhD, described a holistic approach.
The ACR will be back on Capitol Hill Sept. 26 to advocate for lower out-of-pocket costs of prescription drugs and the repeal of arbitrary Medicare therapy caps, as well as to shed light on the role of pharmacy benefit managers (PBMs) in drug pricing. But it will take the voice of all rheumatology professionals and…